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It is widely believed that inﬂuenza (ﬂu) vaccination of the elderly reduces all-cause mortality, yet randomized
trials for assessing vaccine effectiveness are not feasible and the observational research has been controversial.
Efforts to differentiate vaccine effectiveness from selection bias have been problematic. The authors examined
mortality before, during, and after 9 ﬂu seasons in relation to time-varying vaccination status in an elderly California
population in which 115,823 deaths occurred from 1996 to 2005, including 20,484 deaths during laboratory-deﬁned
ﬂu seasons. Vaccine coverage averaged 63%; excess mortality when the ﬂu virus was circulating averaged 7.8%.
In analyses that omitted weeks when ﬂu circulated, the odds ratio measuring the vaccination-mortality association
increased monotonically from 0.34 early in November to 0.56 in January, 0.67 in April, and 0.76 in August. This
reﬂects the trajectory of selection effects in the absence of ﬂu. In analyses that included weeks with ﬂu and
adjustment for selection effects, ﬂu season multiplied the odds ratio by 0.954. The corresponding vaccine effec-
tiveness estimate was 4.6% (95% conﬁdence interval: 0.7, 8.3). To differentiate vaccine effects from selection bias,
the authors used logistic regression with a novelcase-centered speciﬁcation that maybe useful in other population-
based studies when the exposure-outcome association varies markedly over time.
aged; epidemiologic methods; inﬂuenza, human; inﬂuenza vaccines; mortality; selection bias
Abbreviation: VE, vaccine effectiveness.
How effective is inﬂuenza (ﬂu) vaccination in reducing
mortality in the elderly? For several decades, vaccines
against inﬂuenza have been recommended for people aged
65 years or more. It is widely believed that inﬂuenza vacci-
nation saves many lives, especially when the epidemic is
severe and the vaccine match is good. However, it has not
been feasible to conduct randomized trials in the elderly that
could yield compelling evidence about vaccine effective-
ness, and there is controversy over how to interpret the avail-
able research (1).
Observational studies have found that mortality during ﬂu
season is much lower in vaccinated elderly people than in
those not vaccinated (2–7). However, recently investigators
have noticed that morbidity and mortality are relatively low
in vaccinees even before the start of ﬂu season (1, 8–15).
These reports suggest that much or all of the vaccinated-
versus-unvaccinated difference in mortality is attributable to
selection bias. This bias can arise if 1) vaccination rates tend
to be relatively low in people who are most at risk of death
and 2) available data do not permit adequate adjustment for
this tendency.
To differentiate vaccine effects from bias, we traced the
vaccination-mortality association day by day—before, dur-
ing, and after ﬂu season—at Kaiser Permanente in Northern
California. The usual strategy for minimizing bias is to seek
good measures of potential confounders and then adjust for
them. However, usually it is not feasible to track weekly
changes in frailty and function as they attenuate the pro-
pensity to obtain ﬂu shots near the end of life.
Our alternative strategy was to focus on a ‘‘difference in
differences’’ (this term and general approach are often used
by economists (16)). If the ﬂu vaccine really does prevent
deaths, then in a large population there should be a detect-
able difference between 2 differences: 1) the difference in
the odds of prior vaccination between decedents and survi-
vors that is observed on days when ﬂu is circulating and
2) the difference in the odds of prior vaccination between
decedents and survivors that would be expected on the same
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a difference in differences (or the corresponding ratio of
odds ratios), we ﬁtted a logistic regression model with
a novel case-centered speciﬁcation.
Our goals were to: 1) examine the propensity to obtain
a ﬂu shot in relation to predictors of mortality, 2) estimate
the effect of ﬂu shots on mortality, and 3) present and dis-
cuss case-centered logistic regression.
MATERIALS AND METHODS
Setting
Kaiser Permanente in Northern California provides
comprehensive medical services to a membership which
grew from 2.5 million to 3.1 million during the study pe-
riod: the 9 ﬂu years from September 15, 1996, through
September 14, 2005. Each autumn, there is a campaign
to deliver ﬂu shots conveniently and at no cost to Kaiser
Permanente members. Members are ethnically diverse and
similar to the population of California in terms of age, but
somewhat underrepresentative of the poor. The current
study included everyone aged 65 years or older who was
a member of Kaiser Permanente at the start of the ﬂu year
(September 15).
Data
Age, sex, and health plan membership were ascertained
from Kaiser Permanente administrative databases. Vaccine
information was obtained from Kaiser Permanente’s Immu-
nization Tracking System. Mortality data were obtained
from California death certiﬁcate ﬁles, and hospital and
clinic diagnoses were obtained from Kaiser Permanente
clinical and claims databases. Diagnoses made during the
12 months before the ﬂu year were weighted using DxCG
software (DxCG, Inc., Boston, Massachusetts) (17, 18), cre-
ating an insurance risk score designed to predict costs. This
risk score was available only for the last 4 ﬂu years of our
study period. Self-reported health status was obtained from
a satisfaction survey routinely mailed by Kaiser Permanente
to random samples of patients after visits. Twenty-seven
percent of the person-time in the study was among people
who had responded to this survey during the 12 months prior
to the ﬂu year.
Throughout the study period, one of the authors (R. B.)
monitored all laboratory tests done within Kaiser Perma-
nente and identiﬁed the beginning and end of each ﬂu sea-
son, based on the number of inﬂuenza tests and whether
more than 10 percent were positive. The earliest ﬂu season
began on November 9; the latest began on February 16.
Every calendar day except January 20–23 fell outside of
ﬂu season in at least 2 of the 9 years in the study period.
Statistical analysis
Who gets ﬂu shots? Vaccine coverage was graphed in
relation to age, insurance risk score, and the predicted prob-
ability of death at the outset of the ﬂu year. The latter was
obtained by logistic regression, regressing death (during the
entire ﬂu year) on age and sex(in 12 age-sexgroups), the log
of the insurance risk score, and dummy variables for diabe-
tes, coronary artery disease, heart failure, and chronic ob-
structive pulmonary disease. The c statistic summarizing the
ﬁt of this model was 0.82.
Estimation of vaccine effectiveness. Vaccine effective-
ness was estimated through case-centered logistic regres-
sion. We call it ‘‘case-centered’’ because it focuses on the
cases (deaths). Although we used time-varying information
from the entire study population, we conducted the logistic
regression analysis with a data set that had only as many
records as there were deaths. For each day that someone
died, we summarized the relevant information on all similar
people at risk and included it in the record for the decedent.
The dependent variable was the decedent’s vaccination
status. It was compared with the expected odds of vaccina-
tion for the decedent, which were calculated before conduct-
ing the regression analysis. To calculate the expected odds,
we found the stratum (or risk set) comprising people who
were similar to the decedent on the day of death and calcu-
lated the odds of vaccination in the entire stratum including
the decedent. These expected odds were included in the
model as an offset, which in effect is a denominator vari-
able. With the expected odds as a denominator variable on
the right side and the observed odds indicated by vaccina-
tion status on the left side, the model could be used to focus
on the observed-to-expected ratio, which is an odds ratio.
We added measures of time of the year to the right side of
the model in order to account for selection effects over time.
Then we added the indicator of ﬂu season in order to esti-
mate how much of a difference it made in the odds ratio.
This difference is what we sought; it amounted to a differ-
ence in differences. It was exponentiated, yielding a ratio of
odds ratios, and then subtracted from 1 and multiplied by
100 to obtain the vaccine effectiveness (VE) estimate.
Thus, prior to conducting the regression analysis, we de-
ﬁned 39,444 potential strata (risk sets): 12 age-sex groups 3
9 years, each with 365 or 366 days. For each stratum, we
calculated vaccine coverage on that day and stored this in-
formation in a look-up table. Then, for each decedent, we
looked up his or her age-sex group on the day of death and
obtained the odds of vaccination. These odds summarize
what our expectations would be in the absence of any vac-
cine effects or selection effects. For example, given a man
who died on November 1, 2002, at age 82 years, our expec-
tation came from the proportion of all men his age (80–84
years) who were vaccinated between September 15 and
November 1, 2002.
An initial runincluded on the right-hand side of the model
only the offset and an intercept. The intercept coefﬁcient
(after exponentiation) is an estimate of the odds ratio for
the overall study period. We added polynomial terms for
number of days since September 15, days squared, and days
cubed in order to examine the trajectory of the odds ratio
during the course of the ﬂu year. We added indicators of sex,
age group, ﬂu year, and the decedent’s receipt of the pneu-
mococcal vaccine (ever vs. never) to reﬁne our examination
of the trajectory of the odds ratio. Finally, we added the ﬂu
season indicator to ﬁnd vaccine effectiveness, differentiated
from selection effects. We restricted this ﬁnal analysis to the
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through April, the 6 months when inﬂuenza virus ever
circulated.
Similar case-centered logistic regression models were ﬁt-
ted to subgroups deﬁned by age (65–79 years vs.  80 years)
and cause of death (cardiovascular and respiratory causes
vs. all other causes). Vaccine effectiveness should be higher
if the cause of death was respiratory or cardiovascular (and
therefore more likely to be ﬂu-related) and if the age group
was younger (because immune response can decline in the
elderly).
Excess mortality during ﬂu season. Finally, we deter-
mined the average amount of excess (ﬂu-attributable) mor-
tality during ﬂu season by ﬁtting a Poisson regression model
to data on 39,420 person-day strata (12 age-sex groups 3 9
years 3 365 calendar days, combining the 2 extra leap days
with February 28). The count of deaths was regressed on
a ﬂu season indicator and covariates, with the person-time at
risk included as an offset term. The covariates included
number of days since September 15, days squared, an in-
dicator for each ﬂu year, and an indicator for each calendar
month.
RESULTS
The elderly Kaiser Permanente population grew from
273,000 to 387,000 during the study period. There were
115,823 deaths in over 3 million person-years (Table 1).
As expected, death was associated with older age, male
sex, and a history of diabetes, heart disease, heart failure,
or chronic obstructive pulmonary disease. The insurance
risk score was a strong predictor of death: 43% percent of
decedents scored in the highest (riskiest) 10 percentiles.
Self-reported health status was also a strong predictor of
death. It had been ‘‘fair’’ or ‘‘poor’’ for 62% of decedents
versus only 30% overall. Decedents were slightly less likely
than the overall study population to have ever received the
pneumococcal vaccine (53% vs. 56%), yet much less likely
than the overall study population to have received the ﬂu
vaccine in the current year (45% vs. 63%).
Flu vaccination began in early October. Of the 1.9 million
ﬂu shots delivered in the study population from 1996 to
2005, two-thirds were delivered by November 11, 95% by
December 20, and 99% by January 12.
Vaccine coverage increased with age up to age 78 years in
women and age 81 years in men (Figure 1). At older ages,
coverage decreased. Similarly, vaccine coverage bore a cur-
vilinear relation with the insurance risk score. Vaccine cov-
erage peaked in patients whose predicted costs were in the
80th–90th percentiles (Figure 2). In the highest 10 percen-
tiles of predicted cost (which included 43% of deaths), vac-
cine coverage decreased substantially. Vaccine coverage
peaked in people whose predicted probability of death dur-
ing the upcoming ﬂu year was 3.0%–7.4% and fell below
50% in patients whose probability of death within a year
was over 30% (Figure 3). There was also a curvilinear as-
sociation of vaccine coverage with self-reported health sta-
tus: As health declined from ‘‘excellent’’ to ‘‘very good’’ to
‘‘good,’’ vaccine coverage increased from 66% to 72% to
74%; as health status declined further to ‘‘fair’’ or ‘‘poor,’’
coverage decreased to 72% or 66%, respectively.
Next, we examined mortality week by week after vacci-
nation (Figure 4). Among all vaccinees, there were only 0.5
deaths per 100 person-years on the day of vaccination and
the following day, which together comprised week 0; by the
eighth week after vaccination, mortality had increased to 3.1
per 100 person-years. In 3 high-risk subgroups deﬁned by
older age, chronic conditions, and self-reported health sta-
tus, there were similar trajectories: Week 8 mortality
Table 1. Characteristics of Kaiser Permanente Members Aged 65
Years or More, Northern California, 1996–2005
Study Population at
Start of Each
Flu Year
a
(n 5 3,044,531
Person-Years)
Decedents
(n 5 115,823)
No. % No. %
Age group, years
65–<70 975,664 32.1 14,864 12.8
70–<80 1,442,172 47.4 44,257 38.2
80–<90 554,927 18.2 43,337 37.4
 90 71,768 2.4 13,365 11.5
Male sex 1,359,674 44.7 58,802 50.8
Chronic conditions
Chronic obstructive
pulmonary disease
122,158 4.0 14,381 12.4
Diabetes 397,151 13.0 23,061 19.9
Coronary artery
disease
296,548 9.7 22,574 19.5
Heart failure 124,066 4.1 19,981 17.3
Health status
b
Poor 37,090 4.5 7,323 21.2
Fair 210,292 25.2 14,161 40.9
Good 374,671 45.0 9,962 28.8
Very good 178,786 21.5 2,773 8.0
Excellent 32,547 3.9 391 1.1
Percentile of insurance
risk score (predicted
cost)
c
0–<50th 653,407 49.9 6,805 12.8
50–<90th 524,881 40.1 23,300 43.9
90–<98th 104,877 8.0 15,416 29.1
 98th 26,197 2.0 7,522 14.2
Pneumonia vaccination,
ever
1,700,161 55.8 61,520 53.1
Inﬂuenza vaccination
in the current ﬂu year
1,913,728 62.9 51,491 44.5
a Mid-September to mid-September.
b Health status was self-reported and was available only for
patients who were randomly sampled for a visit-based survey about
satisfaction with health care that was routinely conducted by Kaiser
Permanente. Percentages are percentages of the people with data
available.
c Risk scores were available only for ﬂu years 2001–2002 to 2004–
2005. Percentages are percentages of the people with data available.
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in these 3 high-risk groups, respectively. Mortality among
the healthier vaccinees (those with none of these risk fac-
tors) is shown on the lowest line of Figure 4: Although it is
much lower throughout, it increases by a similar trajectory
whereby week 8 mortality is 2.7 times higher than week 1
mortality. Thus, stratiﬁcation by risk factors did not appear
to change the pattern of rising mortality week by week after
vaccination. Beyond week 8, mortality increased more grad-
ually in all groups.
The vaccination-mortality association throughout the ﬂu
year is shown in Figure 5. The triangles show the proportion
vaccinated among decedents by week of death, omitting the
deaths that occurred when the inﬂuenza virus was circulat-
ing. The proportion of decedents who were vaccinated was
always lower than expected, where the proportion expected
comes from vaccine coverage in the decedent’s age-sex
group on the day of death (as described above). The de-
scending line in Figure 5 traces the ‘‘VE’’ estimate for each
week that comes from the corresponding observed and ex-
pected proportions shown on the other 2 lines. This descend-
ing line is labeled ‘‘VE’’ because it is the estimator of
vaccine effectiveness that has been used in many studies,
and quotation marks are used because here it can only reﬂect
bias. Because all deaths occurring during ﬂu season were
omitted, the level of the ‘‘VE’’ line in Figure 5 cannot be
attributed to vaccine effectiveness. Instead we suggest that
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Figure 1. Inﬂuenzavaccine coveragebyage and sexamong elderly
members of Kaiser Permanente, Northern California, 1996–2005.
20
30
40
50
60
70
80
0–9
10–19
20–29
30–39
40–49
50–59
60–69
70–79
80–89
90–94
95–97
98
99
Risk Score Percentile
%
 
V
a
c
c
i
n
a
t
e
d
Figure 2. Inﬂuenza vaccine coverage in relation to insurance risk
score among elderly members of Kaiser Permanente, Northern Cal-
ifornia, 1996–2005. Intervals on the horizontal axis are spaced un-
evenly to sharpen the focus on higher-risk patients.
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Figure 3. Inﬂuenza vaccine coverage in relation to probability of
death among elderly members of Kaiser Permanente, Northern Cal-
ifornia, 1996–2005. Intervals on the horizontal axis are spaced un-
evenly to sharpen the focus on higher-risk patients.
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Figure 4. Mortality (deaths per 100 person-years) by week after in-
ﬂuenza vaccination among higher-risk vaccinees, lower-risk vaccin-
ees, and all vaccinees (1.9 million ﬂu shots), Kaiser Permanente,
Northern California, 1996–2005. The ﬂat reference line shows the
average monthly mortality during all unvaccinated time in the study
population. COPD, chronic obstructive pulmonary disease.
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mortality association when it reﬂects selection bias.
A smoothed estimate of this trajectory—smoothed by
means of case-centered logistic regression—is our point of
departure for differentiating vaccine effectiveness from bias.
When ﬂu season deaths were included, ‘‘VE’’ in ﬂu season
was 4.6% higher than the expected bias.
VE estimates and conﬁdence intervals are shown in
Table 2, after adjustment for the bias. Vaccine effectiveness
against all-cause mortality during ﬂu season was 4.6% (95%
conﬁdence interval: 0.7, 8.3). Vaccination appears to have
been more effective (5.3%) at ages 65–79 years than at older
ages (3.9%). In addition, the vaccine appears to have been
more effective against mortality from cardiovascular and
respiratory causes (8.5%) than against mortality from other
causes (0.1%). However, these differences in vaccine effec-
tiveness by age and cause of death were not statistically
signiﬁcant (P > 0.10).
The analysis of excess (ﬂu-attributable) mortality yielded
results consistent with our inference that vaccine effective-
ness is the reason why the arrival of inﬂuenza strengthened
the vaccination-mortality association: During ﬂu season,
mortality was higher by 7.8% (95% conﬁdence interval:
5.7, 9.9) than at the same time of the year when inﬂuenza
virus was not circulating.
DISCUSSION
We found that ﬂu shots reduced all-cause mortality
among elderly Kaiser Permanente members by 4.6% during
9 laboratory-deﬁned ﬂu seasons in Northern California.
Other researchers have reported that ﬂu shots reduce
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Figure 5. Observed and expected proportions of decedents with inﬂuenza vaccination and the corresponding bias in vaccine effectiveness (VE),
Kaiser Permanente, Northern California, 1996–2005. Deaths occurring during the 9 inﬂuenza seasons were omitted, so ‘‘VE’’ reﬂects bias rather
than effectiveness.
Table 2. Effectiveness of Inﬂuenza Vaccination in Preventing Mortality Among the Elderly During Inﬂuenza
Season, by Cause of Death and Age Group, Kaiser Permanente, Northern California, 1996–2005
Cause of
Death
Age Group,
years
No. of
Deaths
Vaccine
Effectiveness
a,%
95% Conﬁdence
Interval
P
Value
All causes  65 61,436 4.6 0.7, 8.3 0.0212
All causes 65–79 29,743 5.3  0.3, 10.6 0.0641
All causes  80 31,693 3.9  1.6, 9.0 0.1606
Cardiovascular or
respiratory disease
 65 31,798 8.5 3.3, 13.4 0.0017
Other causes  65 29,638 0.1  5.9, 5.8 0.9632
a Vaccine effectiveness was estimated by means of case-centered logistic regression.
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results from 20 cohort and case-control studies, Voordouw
et al. (6) found that ﬂu shots reduce winter deaths by 50%,
on average; and in a more recent study, Nichol et al. (19)
reported a 48% reduction in all-cause mortality among the
elderly during ﬂu season. However, Simonsen et al. (11, 12,
20) found that excess mortality attributable to inﬂuenza has
only been 5%–10% on average during ﬂu seasons in the past
several decades. They argued that ﬂu shots could not possi-
bly have prevented more deaths than the 5%–10% of deaths
that were ﬂu-related (11–13). Our estimate of excess mor-
tality during ﬂu season was 7.8%, which is consistent with
Simonsen et al.’s nationwide estimate but lower than esti-
mates made by others (21–23).
This excess mortality of 7.8% is what we found in a pop-
ulation with over 60% vaccine coverage. Our ﬁndings sug-
gest that had none of the elderly been vaccinated, excess
mortality during ﬂu season would have averaged about
9.8%. We infer that our 4.6% VE estimate amounts to
a 47% reduction (4.6/9.8 ¼ 47%) in the number of ﬂu-
attributable deaths that would have occurred had none of
the elderly been vaccinated.
Mortality in the Kaiser Permanente elderly population
wasapproximately3,804per100,000person-years(Table1).
On average, 683 of these 3,804 deaths occurred during a
laboratory-deﬁned ﬂu season, including 326 deaths in
vaccinees. Our VE estimate of 4.6% implies that in the
absence of ﬂu shots, there would have been 342 ﬂu-season
deaths (326/0.954 ¼ 342) in vaccinees. Thus, vaccination
prevented approximately 16 ﬂu-season deaths per 100,000
person-years (342   326 ¼ 16) in the Kaiser Permanente
population, which amounted to approximately 25 deaths
preventedper100,000peoplevaccinated. Thecorresponding
‘‘number needed to treat’’ was 4,000; in other words, 1 death
was prevented for every 4,000 elderly people vaccinated.
Before estimating vaccine effectiveness, our initial goal
was to examine who gets ﬂu shots. Whereas Nichol et al.
(19, 24) reported that higher-risk patients were more likely
to be vaccinated, Jackson et al. (9) reported that higher-
risk patients were less likely to be vaccinated. We found
a curvilinear relation between predictors of mortality and
vaccination. Perhaps other investigators overlooked the
curvilinearity because they considered mainly dichotomous
indicators of risk. In our population, as in Nichol et al.’s
populations, patients with heart disease, diabetes, or chronic
obstructive pulmonary disease were more likely, on average,
to get ﬂu shots than patients without these chronic condi-
tions. However, most patients with these conditions had
only a moderately elevated risk of death, often in the range
where vaccine coverage was highest. In higher-risk patients,
who drive mortality rates in the upcoming ﬂu season, the
propensity to obtain ﬂu shots waned.
It seems plausible that near the end of life, frailty poses
barriers to vaccination, and patients (and providers) may
tend to ‘‘give up’’ on preventive measures. However, until
then, patients with chronic conditions have more reason and
opportunity to get vaccinated than healthy people, because
patients with chronic conditions tend to be more vulnerable
to inﬂuenza and have more contact with providers who en-
courage vaccination.
Within low-risk subgroups as well as high-risk subgroups,
mortality was low soon after vaccination and then increased
over time in a pattern suggesting selection bias (Figure 4). It
is this rise in mortality with time since vaccination that is
especially challenging in the estimation of vaccine effec-
tiveness. One strategy is to strive for better measures of
frailty for covariate adjustment and for exclusion of patients
known to be near death at the outset of the autumn vacci-
nation campaign. However, Figures 4 and 5 suggest that
whatever it is about nearness to death that suppresses vacci-
nation, it varies markedly over time and would be difﬁcult—
even with data from charts or interviews—to monitor pre-
cisely enough to overcome selection bias.
Rather than seek covariates that might lower the biased
‘‘VE’’ line in Figure 5 and keep it ﬂat at zero outside of ﬂu
season, we implemented a difference-in-differences ap-
proach: We traced the trajectory of the bias over time and
compared the vaccination-mortality association inside ﬂu
season with that outside of ﬂu season. What facilitated this
approach was: 1) access to data on a large study population
over a period of 9 years; 2) substantial year-to-year variation
in the calendar dates of ﬂu season ascertained by laboratory
data; 3) little year-to-year variation in the calendar dates
when ﬂu shots were delivered; and 4) the assumption that
real vaccine effectiveness is negligible each year until ﬂu
season arrives. The potential confounders of our
VE estimate are not the unmeasured aspects of frailty
which confounded Nichol et al. (19); instead, confounders
would have to be somehow associated with the difference in
differences—that is, the difference that the arrival of inﬂu-
enza makes in the vaccination-mortality association.
We examined the difference in differences using case-
centeredlogisticregression.Case-centeredlogisticregression
has several noteworthy features. First, it is closely related to
Cox regression ina cohortstudy. Itisequivalent to a stratiﬁed
Cox model in which death is regressed on a time-varying
indicator of vaccination. Each record in the case-centered
model summarizes an entire risk set in the corresponding
Cox model. The same likelihood is maximized (see the
Web Appendix, which is posted on the Journal’s Web site
(http://aje.oxfordjournals.org/)). Second, case-centered logis-
tic regression is closely related to matched case-control stud-
ies with risk set sampling (also called incidence density
sampling).However,thereisnosampling:Dataareusedfrom
all available controls. Third, it simpliﬁes the analysis of
changes in the exposure-outcome relation. In effect, it makes
the oddsratio the dependent variable, which isthenexamined
in relation to time and other factors. Fourth, case-centered
logistic regression reduces computational burdens dramati-
cally. These can be daunting in large studies with time-
varying exposures. Fifth, it can minimize privacy concerns
in a multisite study. Researchers at the study sites only need
to pool aggregated data about each risk set rather than per-
sonal data about each person.
Our data and ﬁndings have limitations. First, we were
missing data on ﬂu shots given outside of Kaiser Perma-
nente if they were never reported to Kaiser Permanente. If
we missed ﬂu shots delivered in nursing homes to patients
near death, then we exaggerated the bias that we high-
lighted. Second, Kaiser Permanente’s elderly population
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havior near the end of life may vary across sociocultural
settings, and vaccination outreach may vary across practice
settings. Third, our VE estimate was conditional on the
severity of the ﬂu seasons and the match of the vaccines
to circulating strains of the virus. Fourth, we overlooked
herd effects. Fifth, we overlooked late effects (if the vaccine
prevents complications that increase mortality after ﬂu sea-
son). Sixth, the 95% conﬁdence interval around our VE
estimate was wide relative to the excess mortality found in
ﬂu season: The lower bound (0.7%) was not far from zero,
yet the upper bound (8.3%) would amount to the bulk of the
excess mortality that would have struck vaccinees. Seventh,
our focus on mortality overlooked the impact of vaccination
on morbidity.
All-cause mortality is nonspeciﬁc. Nevertheless, it is im-
portant to consider, especially in the elderly. Although our
estimate of 4.6% vaccine effectiveness against all-cause
mortality during ﬂu season may seem disappointing, it
amounts to approximately 47% of a plausible target: the rise
in mortality that would have occurred during ﬂu season had
none of the elderly been vaccinated.
Case-centered logistic regression can be a useful way to
examine change in the impact of a vaccine or treatment as
periods of high risk begin and end. More generally, case-
centered logistic regression can be a useful way to examine
the exposure-outcome association.
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